Dr. Anand Srivastava, M.S., Ph.D. – Chairman, Cofounder and Chief Scientific Officer

 

Dr. Anand Srivastava has been associated with leading universities and research institutions of USA.  In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research projects and has an extensive research experience in the field of Stem cell which is documented by several publications in revered scientific journals.

Dr. Anand Srivastava’s success has its root in his unique background of expertise in Stem cell biology, protein biochemistry, molecular biology, immunology, in utero transplantation of stem cell, tissue targeting, gene therapy and clinical research. There are many scientists who can work in a narrowly defined field but few have broad and multidisciplinary experience to carry out clinical research in a field as challenging as Stem cell biology, cancer and gene therapy field. Dr. Anand Srivastava’s wide-spectrum expertise is rare in clinical research and perfectly crafted to fit ideally with the GIOSTAR projects for Stem cell transplant, cancer and gene therapy research.

Dr. Anand Srivastava’s research work has been presented in various national and international scientific meetings and conferences in India, Japan, Germany and USA. His research articles have been published in peer reviewed medical scientific journals and his work has been cited extensively by other scientists. Dr. Anand Srivastava’s expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the “Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. He has also expertise in genetic engineering research, developmental biology, immunology, making the transgenic animals and his extraordinary expertise of searching and characterizing the new genes are ideal for our ongoing projects of developing the effective treatments for many degenerative diseases, genetic diseases and cancer. Based on his extraordinary scientific achievements his biography has been included in “WHO IS WHO IN AMERICA” data bank two times, first in 2005 and second in 2010. He has been bestowed upon USA Congressional Recognition for his contribution in the field of Stem Cell Science.  

Dr. Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson’s, Alzheimer’s, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Company’s primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

GIOSTAR is world’s leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a world-renowned authority in the field of Stem cell biology, Cancer and Gene therapy.  Several governments and organizations including USA, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership a group of esteemed scientists and clinicians have developed and established Stem cell therapy for various types of autoimmune diseases and blood disorders, which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe.

GIOSTAR is already the official collaborator of Government of Gujarat, India by setting up a state of art stem cell treatment hospital in Surat civil hospital for the less fortunate tribal populace of the southern belt of Gujarat suffering from Sickle Cell Anemia. Several state Governments in India is looking for a collaborative efforts of GIOSTAR and Dr. Anand to develop the  stem cell transplant program in their respective states.

SPECIAL STEM ISSUES OF JOURNALS DEVOTED TO DR. SRIVASTAVA

1. Current Topics of Medicinal Chemistry among top five medicinal chemistry journal devoted its special issue of stem cell to Dr. Srivastava in 2010.
2. Stem Cell International devoted its special issue on stem cells to Dr. Srivastava in 2012.
3. Potentials of ES cell therapy in neurodegenerative diseases (Curr Pharm Des; 2008;14:3873-9) by Dr. Srivastava is still holding number one position among top 20 articles published since 2008 in the field rated by BIoMedLib in 2012.

The following summarizes Dr. Srivastava’s major scientific achievements:

1. Srivastava developed the animal material free and serum free Human embryonic Stem cell culture condition to use the Human ES cells to treat the human diseases.
2. Srivastava for the first time showed that if the ES cell injected into developing fetuses in utero takes participation in development of all body of a living organism.
3. For the first time he showed that ES cell is better accepted by the transplanted animals in comparison to adult stem cells.
4. For the first time he showed the way to generate the high number of pre-erythrocytes using glucocorticoid hormone. Which may be use to treat several blood diseases.
5. For the first time Using ES cells he generated the high number of CD34+ expressing a kind of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune reconstitution and blood diseases.
6. For the first time he showed the molecular mechanism behind the regulation of ES cell differentiation into hematopoietic cells.
7. For the first time he showed that ES cells automatically recognize the damage portion of the brain and can be used to repair the damage brain.
8. For the first time he showed that ES cell can be used to treat the Crohn’s disease a kind of colon cancer.
9. For the first time, he demonstrated that the mammalian fetuses can be programmed inside the mother uterus to face the challenges of the future possible infection. This finding is very important to develop the advanced therapy for any fatal disease such as cancer and AIDS. Utilizing these techniques, fetuses can be given information about all possible infections and the capability to counter those infections and disease.
10. He has demonstrated for the first time that it is easy to correct the genetic diseases in developing fetus in utero in comparison to adult animals.
11. He has shown for the first time that the lung cancer cells can be treated with the help of plant product curcumin and can be used as effective cancer therapeutic agent. He also demonstrated that how curcumin regulated the genes related to programmed death of cancerous cell. Finding help in development of non-toxic, less expensive, easily available drug for cancer.
12. The biggest problem in the treatment of cancer and other diseases is the non-specific distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava for the first time developed a technique that can help in targeting the diseased tissues using the tissue receptor binding peptide ligands. These techniques can be used for targeted delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the mother uterus without harming the normal tissues of mother and fetus.
13. For the first time, He demonstrated the insertion of foreign pancreas enzyme specific gene promoter into the developing animals embryo and successfully shown the incorporation and regulation of pancreatic enzyme in the control of inserted gene. This is very important finding and proves that the defective genes can be replaced easily and effectively by the normal functional genes during the development of animals. This finding will help in the change of defective genes of insulin hormone, which is present in the pancreas of diabetic patients and many other genetic diseases also.
14. For the first time, He reported the gene sequence of all important pancreatic enzymes (three isoform of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three forms of carboxypeptidases and lipase) and its evolutionary relationship with human. Also, he reported first time the regulation of digestion by these enzymes in the alimentary canal during digestion of proteins in the developing animals.
15. For the first time, He cloned and sequenced two types of human homologue of Vitamin D receptor gene from Japanese flounder, which is most important receptor, which help in the development of bone. Before my report, characters of this gene were not known in Japanese flounder. This finding helped in the understanding of the genetic evolution of mammals.
16. For the first time, he cloned and sequenced the homologue of human placental protein, PP11, and mouse T cell specific, Tcl-30, in pancreas of Japanese flounder, this study suggest that these genes evolved from the fish pancreas and in fish it helps in synthesizing the digestive enzymes but during the evolution its function got changed and work differently in the mammalian placenta. This was very important finding related to this rare gene.
17. For the first time, He has shown that the Hox and sonic hedgehog genes regulate the development of bones and respiratory organs. He also demonstrated that how these genes could be regulated artificially. This was very important finding because it gives the idea that how genes regulate the development of organs.
18. For the first time, He has purified and characterized the human homolog of AAT and ASPT enzymes, which is the basic clinical marker in all the infection and major marker of liver function test.
19. For the first time, he demonstrated the co-ordination of AAT and ASPT enzymes in the production of energy through the amino acids after aerobic respiration.
20. For the first time, he has shown that according to metabolic demand of the body AAT and ASPT genes synthesized additional forms of its isoform to cope up with the extra energy demand and work as an “on” and off” switch.

Dr. Srivastava has contributed for Stem cell programs and guided stem cell policies and programs for following governments and private organizations:

1. Helped stem cell core facility at Salk Research Institute, San Diego, USA
2. Worked for stem cell program at University of California, Los Angeles, USA
3. Worked for Japanese Research Institute for developing genomic program, Japan
4. Guided scientists in developing stem cell program for Turkey, Kuwait and Saudi Arabia
5. Stem cell program Director of GIOSTAR for State of Gujarat, India
6. Stem cell program Director of GIOSTAR for State of Madhya Pradesh, India
7. Stem cell program Director of GIOSTAR for State of Chhattisgarh, India
8. Stem cell program Director of GIOSTAR for University of Baroda, Gujarat, India
9. Stem Cell program advisor for Asian Medical School, Kyrgyzstan

POSITIONS HELD BY DR. SRIVASTAVA (1997 to Date):

1. Chairman & Cofounder: Global Institute of Stem Cell Therapy and Research, San Diego, CA. USA.
2. Visiting Associate Researcher: Department of Molecular, Cell and Development Biology, University of California Los Angeles (UCLA), CA, USA.
3. Visiting Researcher: Department of Stem Cell Biology, Burnham Research Institute for Medical Science, San Diego, CA, USA.
4. Researcher : Stem Cell Core Facility, The Salk Research Institute, La Jolla, CA, USA.
5. Associate Project Scientist: Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA.
6. Assistant Project Scientist: Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
7. Visiting Fellow: National Research Institute, Nansei, Mie, JAPAN

EXPERT SCIENTIFIC REVIEWER FOR LEADING JOURNALS OF MEDICINE:

Dr. Srivastava is the member of the several scientific review committees and reviewing the research grants. He has written several review articles and scientific manuscripts. He is also the reviewer of several scientific journals.

1. Advances in Stem Cells
2. Current pharmaceutical Design
3. Current Topics in Medicinal Chemistry
4. Stem Cells
5. Stem Cell International
6. Current in Cell Medicine
7. Journal of Stem Cell Research and Therapy
8. Conference Papers in Molecular Biology
9. Journal of Pharmaceutics
10. Current Pharmaceutical Biotechnology
11. Open Journal of Organ Transplant Surgery
12. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry‏
13. Stem Cells and Cloning: Advances and Applications
14. Blood and Lymphatic Cancer: Targets and Therapy
15. Degenerative Neurological and Neuromuscular Disease
16. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
17. Immuno Targets and Therapy
18. Current Vascular Pharmacology
19. Gastrointestinal Cancer: Targets and Therapy
20. Journal of Bioengineering and Biomedical Sciences
21. The Application of Clinical Genetics
22. Journal of Tissue Science & Engineering
23. Neuropsychiatric Disease and Treatment
24. Current Tissue Engineering
25. Hepatic Medicine: Evidence and Research
26. Current Drug Discovery Technologies
27. Current Bioactive Compounds
28. Transplant Research and Risk Management
29. Biosimilars
30. Current Drug Delivery
31. Journal of Experimental Pharmacology
32. Open Journal of Regenerative Medicine
33. Current Diabetes Reviews
34. Journal of Fertilization: In Vitro
35. Clinical and Translational Medicine

FELLOWSHIPS/ AWARDS:

2020	Dr. Anand Srivastava, Ph.D. received an Outstanding Achievement Award from the Society of American Asian Scientists in Cancer Research (SAASCR) alongside top nine Cancer Researchers of America.
2014	Awarded with “USA Congressional Award” for his contribution in the field of Stem Cell Science. USA.
2013	Awarded with “Asian Heritage Award” for his contribution in the field of Stem Cell Science. USA.
2003	Awarded with “NIMA (National Integrated Medical Association) Outstanding Scientist” award from NIMA, India.
2003	Awarded with “Excellent Scientist Award” from Bharat Vikas Parisad, India for continuous excellent performance in the life science research.The 18th International Congress of Clinical Chemistry and Laboratory Medicine Kyoto“Excellent Poster Award”, Kyoto, Japan.
2002	“Best Scientist Award” for excellent contribution in the field of life science research from Kayastha Maha Sabha, Varanasi, India.
1998-2000	“Long-term STA/JISTEC Award” (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship award for two year from government of Japan.
1997-1998	“Short-term STA/JISTEC Award” (Science and Technology Agency/Japan International Science and Technology Exchange Center, JAPAN)- Fellowship Award for three months from government of Japan (October 1997- January 1998).
1997-1998	Awarded with “Research Associate-ship award” from CSIR (Council of Scientific and Industrial Research) Government of India.
1990-1995	“CAS (Center of Advanced Study) Award” in Zoology. A doctoral research fellowship award from Government of India.

GRANTS AND AWARDS FUNDING RELATED TO DR. ANAND SRIVASTAVA’S WORK

1. Government of India grant to establish Red Blood Cell from Stem cell (2015 to 2017)
2. Canada Grand Challenge grant award, Canada, Development of tuberculosis (TB) test in TB patients, (2013-2014).
3. Government of India grant to establish stem cell transplant center (2009 – till date).

4. Broad Medical Research Program, Repair of Crohn’s Disease with Stem Cells, (2004-2005)
5. National Institute of Health, USA (NIH/NIDDK R01 grant), Mixed Chimerism Following Prenatal Tolerance Induction, (1999-2005).
6. Ronald McDonald House Charities Medical Grant, Lentiviral Gene Transfer in ß-Thalassemic Mice, (2000-2005).
7. National Institute of Health, USA (NIH-K08 grant), In utero transplantation of stem cell in ß-thalassemic mice, (2000-2002)
8. Japan Science and Technology award (JISTEC Grant), Government of Japan, Cloning and gene expression during development (1988-2000).
9. Japan Science and Technology award (JISTEC Grant), Government of Japan, Expression of enzymes and protein during energy metabolism (1997-1998).
10. Center of Scientific and Industrial Research (CISR) grant, Government of India under young scientist award (1996-1997).

DR. SRIVASTAVA’S EXCELLENCE IN SEVERAL ADVANCED BIOLOGICAL TECHNIQUES:

Techniques related to Human Embryonic Stem Cell

Human Embryonic Stem cell culture, Serum free and feeder free hES cell culture, in vitro differentiation of hES cells into neural cells, in vitro differentiation of hES into hematopoietic cells and red blood cells under the control of cytokines. Gene regulation studies using RT-PCR, Real time PCR, Northern blot, Southern blot and in situ hybridization, immunohistochemistry during the differentiation, Cell cycle regulation studies during differentiation of hES cells into hematopoietic and neural cells. Use of siRNA for blocking a specific cell cycle. FACS analysis of differentiated cells and cell shorting. ES cell transfection.

In vivo studies with ES cells

Created a mouse model for study the effect of ES cells on damaged brain. Injection of ES cells into mouse brain, tail vein injection, in vivo tracking of ES cell migration. Used the ES cells for repair of damaged brain. Gene and protein regulation during neural cell differentiation. Studies on transcription factors. Histochemical analysis of transplanted ES cells using fluorescent, confocal microscopy and deconvolution microscopy.

Created a mouse model for Crohn’s disease. In vivo migration of ES cells into diseased portion of intestine. Studies on inflammatory cytokines during the repair of Crohn’s disease with ES cell. Gene regulation studies during this process. Elisa assays for the cytokines. Stem cell niche interaction.

Created in utero mouse model for ES cells transplantation. Used this model to make chimeric animals. Distribution and differentiation of ES cells into developing mouse embryo. FACS and magnetic shorting of ES cells derived CD31+, CD34+, CD45+ cells from the transplanted animal tissues. Gene and protein regulation of in vivo differentiating cells.

Created immunocompromised mouse model to study the effect of in vivo immune component on T7 phage virus. In vivo selection of tissue specific receptor binding peptide using in vivo biopanning method. Tissue targeted gene delivery to correct the blood related genetic diseases. Gene cloning, gene sequencing, synthesis of RNA probes.

Protein and enzyme biochemistry

Protein assay, peptide structure and amino acid sequencing, Enzyme assay, Ultra centrifugation, Ion exchange chromatography, column chromatography, HPLC, Protein and gene regulation during the development. Enzyme kinetics, Enzyme inhibition, SDS gel electrophoresis, Protein characterization.

Selection of cell receptor binding peptide and Phage display technology

• Selection of tissue receptor binding peptides using T7 phage display system.
• In vivo and in vitro biopanning for selection of receptor binding peptides sequences.
• Characterization of targeted cells and tissues using histochemistry and gene expression analyses.
• In vivo delivery of drugs and genes to targeted tissues using microinjection.

Cancer Research 

• Studying the role of pharmaceutical agent curcumin as an anti-lung cancer drug and develop it as a non-toxic cancer drug.
• Role of apoptotic genes on the lung cancer cell lines.
• Development of tissue targeted delivery protocol of pharmaceuticals agents for cancer and genetic diseases.

Fluorescence techniques for nucleic acid sequence detection: Clinical and diagnostic applications

–     Fluorescent labeling of DNA and RNA probes.

• Fluorescence resonance energy transfer (FRET) protocols for DNA and RNA sequence.

      detection  in real time (Sequence Detection System 7700, ABI, Perkin Elmer)

• FRET protocols for monitoring ribozyme reactions and kinetics in real time (TaqMan, SDS 7700, ABI, Perkin Elmer).
• Accessibility studies for DNA and RNA target sequences using FRET.
• Fluorescence polarization protocols for monitoring ribozyme reactions (POLARstar, BMG, GmbH) and for DNA and RNA sequence detection.
• Sequence detection with Syber green dye in real time quantitative PCR by Light Cycler (Roche Diagnostics, USA).
• Single nucleotide polymorphism detection in real time with LightCycler hybridization probes (Roche Diagnostics, USA).

Gene detection technology: Research and Clinical applications

• Preparation of radio labeled & fluorescent labeled RNAs (ribozymes and target substrates).
• In vitro transcription of RNA.
• Expression of ribozymes in yeast.
• Isolation and purification of cellular RNA.
• RNase Protection Assay.
• Kinetic characterization of ribozymes & binding kinetics using fluorescence methods.
• Designing, synthesis and characterization of allosteric ribozymes induced by small drug ligands (such as theophylline & caffeine).
• Developed in utero microinjection techniques to transplant the bone marrow and stem cells to cure blood related genetic disease.
• Harvest the fetal liver, bone marrow and mouse embryonic stem cells for transplantation.
• Culture mouse embryonic stem cell and in vitro differentiation into the blood cells.
• Fractionation of cells using flow cytometry techniques.

Standard Molecular biology techniques

• Standard and site directed mutagenesis polymerase chain reaction (PCR).
• Preparation and purification of plasmids.
• Transformations and Transfection of DNA.
• Cloning of DNA.
• Solid phase synthesis of DNA (Gene Assembler, Pharmacia).
• DNA sequencing & fragment analyses (ABI 310 Gene Sequencer, Perkin Elmer).
• Quantitation of DNA, RNA and proteins.
• Mammalian cell culture and yeast culture.
• Gel electrophoresis (polyacrylamide and agarose).
• Capillary gel electrophoresis (ABI 310 Gene Sequencer, Perkin Elmer).
• Column/ gel/ thin layer chromatography.
• Autoradiography by phosphorimager (Storm, Molecular Dynamics, USA).
• High Performance Liquid Chromatography (HPLC).
• Preparation and purification of chemical reagents & solvents.
• Enzyme/ Protein/ purification and characterization.
• Isolation of Genomic DNA, Genomic library Construction.

–    Radioimmunoassay.

General molecular and biochemical techniques

mRNA preparation and purification, Primer designing, Real-time PCR, RT-PCR, DNA cloning, DNA sequencing, Isolation of Genomic DNA, Genomic library Construction, Transformation, Transfection, Cell culture, Plasmid purification, RNA probe making, Different kinds of microscopy, In situ hybridization, Southern blotting, Northern blotting, Western blotting, Spectrophotometery, In utero-microinjection, Column chromatography, HPLC, PAGE, Agarose gel-electrophoresis, Enzyme assay, Protein assay, Enzyme/ Protein/ DNA purification, Histology, Phage display for tissue targeting, Radio-immunoassay.

Autologous stem cell transplant techniques

Developed the techniques to isolate the autologous stem cell from patient’s peripheral blood, bone marrow or fat tissues, characterize and activate those stem cells so they can be effectively used for the treatment of specific diseases.

INVITED SPEAKER AND PRESENTATIONS OF DR. SRIVASTAVA’S SCIENTIFIC FINDINGS IN NATIONAL AND INTERNATIONAL CONFERENCES:

1. Srivastava A.S. Invited to chair the session at 8th Annual World Congress of Regenerative Medicine & Stem Cell-Korea. South Korea, March 2015.
2. Srivastava A.S. Invited Speaker “5^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery System” at Dubai, UAE, March 2015.
3. Srivastava A.S. “4^thInternational Conference on Neurology and Epidemiology” at Malaysia, Kuala Lumpur, November 2014.
4. Srivastava A.S. Invited Speaker “3^rd International Conference on Translational Medicine ” at Las Vegas, USA, November 2014.
5. Srivastava A.S. “7^th Annual Clinical Trials on Alzheimer’s Disease ” at Philadelphia, USA, November 2014.
6. Srivastava A.S. “4^thWorld Congress on Cell Science & Stem Cell Research” at Valencia, Spain June 2014.
7. Srivastava A.S. Invited Speaker, STEM 2013, 9^ThAnnual Conference on Biotechnology – Focusing On Latest Trend in Stem Cells, Regenerative Medicine and Tissue Engineering Mumbai, India, January 2013
8. Srivastava A.S. “International Conference on Regenerative and Functional Medicine” (Regenerative Medicine-2012), San Antonio, USA. November 2012.
9. Sriavstava A.S. 2nd International Congress on Neurology & Epidemiology; “Impact of drugs on the natural history of neurological diseases”. Nice, France. November 2012.
10. Srivastava A.S. Invited Speaker, International Expo and Conference on Analytrix & HPLC, Chicago, USA. October 2012.
11. Srivastava A.S. Invited Speaker at “International Conference on Emerging Cell Therapies” (Cell Therapy-2012) Chicago, USA. October 2012.
12. Srivastava A.S. Invited Speaker, 6th Neurodegenerative Conditions Research and Development Conference San Francisco, CA, USA. September 2012
13. Srivastava A.S. 8th International Congress on Mental Dysfunction & Other Non-Motor Features In Parkinson’s Disease and Related Disorders, Berlin, Germany. May 2012
14. Srivastava A.S. International Conference and Exhibition on Neurology & Therapeutics Las Vegas, USA. May 2012.
15. Srivastava A.S. Montreal International Biotechnology Forum, Montreal, Quebec, Canada. May 2012.
16. Srivastava A.S.  Invited Speaker, International Association of Neurorestoratology (IANR) V and 9th Global College Neuroprotection and Neuroregeneration (GCNN) conference with the 4th International Spinal Cord Injury Treatment & Trial Symposium (ISCITT) Xi’an City, China. May 2012.
17. Srivastava A.S. International Forum on the Mediterranean Diet, Ravello – Amalfi Coast, Italy. March 2012
18. Srivastava A.S. Hong Kong international Stem Cell Forum 2012, Hong Kong. February 2012.
19. Srivastava A.S. 4^th International Conference on Drug Discovery and Therapy” (4^th ICDDT 2012) Dubai, UAE, February 2012.
20. Srivastava A.S. Evolving Strategies in Hematopoietic Stem Cell Transplantation- San Diego, USA. February 2012.
21. Srivastava A.S. Hebei International Biotechnology Forum; Shijiazhuang, Hebei, China. November 2011
22. Srivastava A.S. 3rd International Conference on Drug Discovery and Therapy. Regenerative Medicine. Dubai, UAE. February 2011.
23. Srivastava A.S. 3^rd Annual Congress of Regenerative Medicine & Stem Cell-2010, Shanghai, China. December 2010.
24. Srivastava A.S. 1^st Annual Tetra-Congress of MolMed-Personal Medicine Congress 2010, Shanghai, China. November 2010.
25. Srivastava A.S. International Association of Neurorestoratology(IANR), American Journal of Neuroprotection and Neuroregeneration, Beijing, China. October 2010.
26. Srivastava A.S. EPS Global International Neuroscience Forum. Nha Trang, Vietnam. October 2010.
27. Srivastava A.S. EPS Global International Neuroscience Forum, Guangzhou, China. September 2010.
28. Srivastava A.S. 4th Academic Congress of International Chinese Neurosurgical Sciences. Chengdu, China. June 2010.
29. Srivastava A.S. 1^st Annual World Congress of Immunodiseases and Therapy (WCIT 2010). Beijing, China. May 2010.
30. Srivastava A.S. 3rd PepCon-2010 – Protein Misfolding and Neurodegeneration. Beijing, China. March 2010
31. Srivastava A.S. Potential use of ES cells in hematopoietic and neural diseases. City of Hope National Medical Center, Duarte, California, USA. January, 2009.
32. Srivastava A.S. Differentiation of Human Embryonic Stem cell into erythrocyte and neural precursor cells: Its potential application. Cleveland Clinic, Cleveland, Ohio, USA, December, 2008.
33. Srivastava A.S. Potential of ES cell in repair of Hematopoietic and neural diseases. International Conference in Stem cell, Kerala, India, August, 2008.
34. Srivastava A. S., Singh U. and Carrier E. Embryonic stem cell improve colitis and decrease IL-12 levels in the colitis mice. BMRP Fourth Annual Investigator Meeting, Los Angeles, USA. 2006
35. Carrier E., Shermila Kausal and Srivastava A. S. Gene Regulation During the Erythrocytic Differentiation of Embryonic Stem Cells. Blood (ASH Meeting), 2005.
36. Carrier E., Shermila Kausal and Srivastava A. S. Differentiation of Human ES cell into the Hemangioblast. Blood (AHS Meeting), 2005.
37. Srivastava A.S., Zhongling F., Victor A., Kim H.S. and Carrier E. Repair of Crohn’s disease with embryonic stem cells. Broad Medical Research Program, Third Annual Investigator Meeting, Los Angeles, CA, USA, 2005.
38. Srivastava A.S., Shenouda S. and Carrier E. Damaged murine brain induces ES cells into migration and proliferation. Blood:104, 779a, 2004.
39. Srivastava A.S., Shenouda S. and Carrier E. Increased expression of OCT4,SOX2 and FGF4 genes following injection of embryonic stem cell into damaged murine brain. American Society of Gene Therapy, 2004.
40. Srivastava A.S. and Carrier E.; Distribution and stability of T7 phage in mouse blood and tissues. Molecular Therapy:7, 230, 2003.
41. Moustafa M., Srivastava A.S., Nedelcu E., Minev B., Carrier E.; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. 32^nd annual meeting of the international society for Experimental Hematology, 31, 274, 2003 (Paris, France).
42. Steve S., Srivastava A.S. Carrier E.; In vivo survival of hematopoietic stem cell in mouse brain.11^th international symposium on recent advances in Stem cell transplantation, 89-90, 2003 (San Diego, USA).
43. Srivastava A.S., Carrier E.; Distribution and stability of T7 phage in mouse. 11^th international symposium on recent advances in Stem cell transplantation, 93, 2003 (San Diego, USA).
44. Elena N., Srivastava A.S., Varki N.M., Assatourian G. and E. Carrier; Embryonic stem cells survive and proliferate after intraperitoneal In utero transplantation and produce teratocarcinomas. Blood:160b, 2002.
45. Srivastava A.S and E. Carrier; In utero targeting the fetal liver by using T7 phage display system. Blood:489b, 2002.
46. Srivastava A.S. and E. Carrier; Factor responsible for in vivo neutralization of T7 phage display vector in the blood of mice. Blood:489b, 2002.
47. Srivastava A.S. and E. Carrier; Distribution and stability of T7 phage in the mouse after intravenous administration. ICCC, Kyoto, Japan. (October 2002).
48. Srivastava A.S., T. Kaido and E. Carrier; Immunological factors that affect the in vivo fate of T7 phage in the mouse. Molecular Therapy:5, 713, 2002.
49. Srivastava A.S., E. Nedelcu and E. Carrier; Engraftment of murine embryonic stem cells after in utero transplantation. Molecular Therapy:5, 1132, 2003.
50. M. Rizzi, T. Kaido, M.Gerloni, K.Schuler, A. S. Srivastava, E.Carrier and M. Zanetti; Neonatal T cell immunity by in utero immunization. AAI 2002 annual meeting, April 20 – 24, New Orleans, Experimental Biology 2002 sponsored by 7 FASEB societies.
51. Srivastava A.S., T. Kaido and E. Carrier; Kinetics of T7 phage neutralization in the blood of normal and immunodeficient mice. Blood:407, 2001.
52. Hassan S., Jody D., Srivastava A.S., T.H. Lee, M.P. Busch, Carrier E.; Immunity without microchimerism after in utero transplantation of Hematopoietic stem cell. Blood:320, 2001.
53. Srivastava A.S., Felix Tinkov, T. Friedmann and E. Carrier; Detection of T7 phage in the fetus after Systemic administration to pregnant mice. Molecular Therapy:4, 760, 2001.
54. Pillai G.R., Srivastava A.S., Hassan S., Carrier E. Differential sensitivity of human lung cancer cell lines to curcumin. 9^th Annual International Symposium on Recent Advances in Hematopoietic Stem cell Transplantation. USA. 2001.
55. Hassan S., Jody D., Srivastava A.S., Carrier E.; The role of I-E molecule on survival rate and tolerance after in utero transplantation. The 42 ASH meeting, San Francisco, USA. 2000.
56. Suzuki T., Srivastava A.S., Kurokawa T.; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, April 2 – 4, 2000, Tokyo, JAPAN.
57. Srivastava A.S., Suzuki T., Kurokawa T., Kamimoto M., Nakatsuji T.; GFP expression in pancreas of developing fish embryo under control of Carboxypeptidase A promoter. Plant and Animal Genome-VIII (PAG-VIII), Conference, San Diego, California, USA. January 9th to 12th, 2000.
58. 58. Srivastava A.S., Suzuki T., Kurokawa T.; Molecular cloning of serine protease cDNAs from pancreas of Japanese flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, Tokyo, JAPAN. 1999.
59. Suzuki T., Srivastava A.S., Kurokawa T.; Cloning of FGFRs from Flounder embryos, and their expression during axial skeletal development. 32nd Annual Meeting of the Japanese Society of Developmental Biologists. JAPAN. 1999.
60. Suzuki T., Srivastava A.S., Kurokawa T.; Expression of Signal molecules during axial skeleton development in Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.
61. Suzuki N., Suzuki T., Srivastava A.S., Kurokawa T.; cDNA cloning and expression analysis of receptor for calcitonin and calcitonin related peptide from Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.
62. Srivastava A.S., Trigun S.K., Singh S.N.; Purification and kinetics of cytosolic aspartate aminotransferase from liver of air-breathing and non air-breathing fish. National Symposium on Comparative Physiology & Endocrinology, Raipur, INDIA. 1997.
63. Srivastava A.S., Trigun S.K., Singh S.N.; Cytosolic alanin aminotransferase from air-breathing and non air- breathing fish. Proceedings of the Symposium on Frontier Topics in Biochemistry and Molecular Biology, Banaras Hindu University, Varanasi, INDIA. 1996.
64. Srivastava A.S., Trigun S.K., Singh S.N.; Studies on aspartate aminotransferase during reproductive cycle of C. batrachus and L. rohita. Proceeding of the 65^th Annual Meeting of the Society of Biological Chemists, I.I.Sc., Banglore, INDIA. 1996.
65. Srivastava A.S., Singh S.N.; A comparison of cytosolic and mitochondrial aminotransferases in fishes. Proceedings of the 4th Convention of Indian Society of Agricultural Biochemist, Banaras Hindu University, Varanasi, INDIA. 1995.

SCIENTIFIC PUBLICATIONS: (Total more than 50 Publications)

1. 1. Cardiovascular diseases: Recent developments in regenerative medicine.
      Mahmood, A., Pandya, H., Rajasekar,S., Patel, D., Srivastava A.. Journal of Stem Cell Research & Therapeutics. 2017, July 3(2):00095. doi: 10.15406/jsrt.2017.03.00095.
   2. Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice.
      Sharma V, Nayak J, DeRossi C, Charbono A, Ichikawa M, Ng BG, Grajales-Esquivel E, Srivastava A, Wang L, He P, Scott DA, Russell J, Contreras E, Guess CM, Krajewski S, Del Rio-Tsonis K, Freeze HH. FASEB J. 2014 Apr 28(4):1854-69. doi: 10.1096/fj.13-245514.
   3. Basal expression of pluripotency-associated genes can contribute to stemness property and differentiation potential.
      Dadheech N, Srivastava A, Belani M, Gupta S, Pal R, Bhonde RR, Srivastava AS, Gupta S. Stem Cells Dev. 2013 Jun 15;22(12):1802-17. doi: 10.1089/scd.2012.0261.
   4. Therapeutic potential of mesenchymal stem cells in regenerative medicine.
      Patel DM, Shah J, Srivastava AS., Stem Cells Int. 2013 Feb 496218. doi: 10.1155 / 2013 / 496218.
   5. Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice. Vandana Sharma, Jonamani Nayak, Charles DeRossi, Adriana Charbono, Mie Ichikawa, Bobby Ng, Erika Esquivel, Anand Srivastava, Ling Wang, Ping He, Joseph Russell, Emily Contreras, Cherise Guess, Stan Krajewski, Katia Del Rio-Tsonis, Hudson H Freeze; Journal Clin. Invest. (Communicated 2013).
   6. Patel DM, Shah J, Srivastava AS., Therapeutic potential of mesenchymal stem cells in regenerative medicine, Stem Cells Int. 2013;2013:496218
   7. Dadheech N, Srivastava AS, Belani M, Gupta S, Pal R, Bhonde RR, Srivastava AS, Gupta S.,
   8. Basal expression of pluripotency-associated genes can contribute to stemness property and differentiation potential. Stem Cells Dev. 2013 Jun 15;22(12):1802-17.
   9. Srivastava AS, Stem cells., Curr Top Med Chem.;11:1591, 2011.
   10. Dhawan P, Ahmad R, Srivastava AS, Singh AB., Cancer stem cells and colorectal cancer: an overview. Curr Top Med Chem. 11:1592-8, 2011.
   11. Sudip Mandal, Anne Lindgren, Anand Srivastava and Utpal Banerjee. Role of mitochondria in self-renewal, early differentiation and tumorigenicity of pluripotent stem cell. Stem Cells, 29:486-95, 2011.
   12. 7. Basak GW, Yasukawa S, Alfaro A, Halligan S, Srivastava AS, Minev B, Carrier E. Human embryonic stem cells hemangioblast express HLA-antigens. J Transl. Med., 7:27-36; 2009.
   13. Grzegorz Wladyslaw Basak, Srivastava AS, Rakesh Malhotra, Ewa Carrier^. Multiple Myeloma Bone Marrow Niche. Curren. Pharm. Biotech, 10:345-6, 2009.
   14. Srivastava AS, Malhotra R, Jason Sharp and Berggren T. Potentials of ES Cell therapy in Neurodegenerative Diseases. Curren. Pharm. Design, 14:3873-9; 2008.
   15. Anand S. Srivastava, Rangnath Mishra, Sharmeela Kausal, Dharam P. Chauhan and Ewa Carrier; Clinical Prospects of Embryonic Stem Cells in treatment of Hematopoietic Disorders. Curren. Pharm. Biotech. 8: 51-56, 2007.
   16. Anand S. Srivastava, Elena Nedelcu, Babak Esmaeli-Azad, Rangnath Mishra and Ewa Carrier; Thrombopoietin Enhances Generation of CD 34+ Cells from Human Embryonic Stem Cells. Stem Cells, 25:1456-61, 2007.
   17. Anand S. Srivastava, Dharam Chauhan, Zong Ling Feng, Hyun S Kim and Ewa Carrier; Transplantation of embryonic stem cell in CDIL10-/- KO mouse, an animal model of colitis, antagonizes the manifestation of Crohn’s Disease. BBRC 361:953-959, 2007.
   18. Anand S. Srivastava, Steve Shenouda, Rangnath Mishra and Ewa Carrier; Transplanted Embryonic Stem cells Successfully Survive and Proliferate in Brain and Migrate to Damaged Regions of the Brain. StemCells, 24:1689-94, 2006.
   19. Anand S. Srivastava, Sharmeela Kaushal, Rangnath Mishra, Thomas A. Lane and Ewa Carrier; Dexamethasone facilitates erythropoiesis in murine embryonic stem cell differentiating into hematopoeitic cells in vitro. BBRC, 346:508-16, 2006.
   20. Marta R., Mara G., Srivastava A.S., Matthew, C. W., Kilian S., Carrier E., and Zanetti M.; Immunity over tolerance targeting fetal liver B cells. Vaccine, 23:4273-82, 2005.
   21. Feng Z, Srivastava AS, Mishra R, Carrier E., A regulatory role of Wnt signaling pathway in the hematopoietic differentiation of murine embryonic stem cells. Biochem. Biophys. Res. Commun., 324:1333-9, 2004
   22. Srivastava A.S., Chauhan, D.P. and Carrier E.; In utero detection of T7 phage in the fetal tissues after systemic administration to pregnant mice. Biotechniques, 37:81-83, 2004.
   23. Srivastava A.S., Kaido T., Carrier E.; Immunological factors that affect the in vivo fate of T7 phage in the mouse. J of Virol. Meth., 115:99-104, 2004.
   24. Srivastava A.S, G. Radhakrishna Pillai, Dharam P. Chauhan and Ewa Carrier; Induction of apoptosis in human lung cancer cells by dietary Curcumin. Cancer letters, 208:163-170, 2004.
   25. M. E. Moustafa, A. S. Srivastava, E. Nedelcu, S. Shenouda and E. Carrier; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. Transplantation, 78:1274-1282, 2004.
   26. A. S. Srivastava, M. E. Moustafa, S. Shenouda, D. P. Chauhan and E. Carrier; In utero gene therapy: prospect and future. Curren. Pharm. Des., 10:3663-72, 2004.
   27. Anand S. Srivastava, Ichiro Oohara, Tohru Suzuki, Steve Shenouda, Surender N. Singh, Dharam P. Chauhan and Ewa Carrier; Purification and properties of cytosolic alanine aminotransferase from the liver of two fresh-water fish species, Clarias batrachus and Labeo rohita. Comp. Biochem. Physiol-B, 137:197-207, 2004.
   28. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A1 mRNA for type 1 collagen alpha 1, complete cds. Nat. Cent. Biotech. Infor., USA, AB196513, 2004.
   29. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A2 mRNA for type 1 collagen alpha 2, complete cds. Nat. Cent. Biotech. Infor., USA, AB196514, 2004.
   30. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A3 mRNA for type 1 collagen alpha 3, partial cds. Nat. Cent. Biotech. Infor., USA, AB196515, 2004.
   31. Suzuki,T., Srivastava, A.S. and Kurokawa,T.,  Paralichthys olivaceus COL1A1 gene for type 1 collagen alpha 1, promoter region. Nat. Cent. Biotech. Infor., USA, AB196516, 2004.
   32. Suzuki,T., Srivastava,A.S. and Kurokawa,T., Paralichthys olivaceus COL1A3 gene for type 1 collagen alpha 3, promoter region. Nat. Cent. Biotech. Infor.,  USA, AB196517, 2004.
   33. Srivastava A.S., Kurokawa T., Suzuki T.; Molecular cloning and cDNA sequence analysis of carboxypeptidases A1, A2 and B from the Japanese flounder Paralichthys olivaceus. Comp. Biochem. Physiol-B, 135:593-599, 2003.
   34. Hassan S., Jody D., Gilpin E.A., Srivastava A.S., Carrier E.; Tolerance and immunity following in utero transplantation of allogeneic fetal liver cells: The cytokine shift. Cell Transplantation, 12:75-82, 2003.
   35. Tohru Suzuki, Anand S. Srivastava, Tadahide Kurokawa; A homologue of human placental protein, PP11, and mouse T cell-specific, Tcl-30, in exocrine pancreas of a teleost Paralichthys olivaceus. Comp. Biochem. Physiol-B, 133:325-329, 2002.
   36. Anand S. Srivastava, Tohru Suzuki, Tadahide Kurokawa; mRNA expression of pancreatic enzyme precursors and estimation of protein digestibility in first feeding larvae of the Japanese flounder, Paralichthys olivaceus. Comp. Biochem. Physiol-A, 132:629-635, 2002.
   37. Hassan S., Jody D., Srivastava A.S., Gilpin E., Lee T, Carrier E.; Alloreactivity following in utero transplantation of cytokine-stimulated hematopoietic stem cells: The role of recipient CD4^– cells. Exp. Hematol., 30:617-624, 2002.
   38. Tohru Suzuki, Anand S. Srivastava, Tadahide Kurokawa; cDNA Cloning and phylogenetic analysis of pancreatic serine proteases from Japanese flounder, Paralichthys olivaceus. Comp. Biochem. Physiol-B, 131:63-70, 2002.
   39. Suzuki, T., Srivastava, A.S. and Kurokawa, T; Paralichthys olivaceus ppsb mRNA for pancreatic protein with two somatomedin B domains. Nat. Cent. Biotech. Infor.,  USA,AB035673, 2002.
   40. Tohru Suzuki, Tadahide Kurokawa, Anand S. Srivastava; Induction of bent cartilaginous skeletons and undulating notochord in flounder embryos by disulfiram and α, ά- Dipyridyl. Zoological Science, 18:345-351, 2001.
   41. Tohru Suzuki, Nobuo Suzuki, Anand S. Srivastava, Tadahide Kurokawa; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Bichem. Bio. Res. Commu. 270:40-45, 2000.
   42. Suzuki,T., Suzuki,N., Srivastava, A.S and Kurokawa,T; Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete sequence. Nat. Cent. Biotech. Infor., USA, AB037673, 2000.
   43. Suzuki,T., Suzuki,N., Srivastava, A.S and Kurokawa,T;Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete sequence. Nat. Cent. Biotech. Infor., USA, AB037674, 2000.
   44. Suzuki,T. and Srivastava, A.S; Keratin expressed at esophagus and skin of flounder larvae. Nat. Cent. Biotech. Infor.,  USA, AB049616, 2000.
   45. Suzuki T., Srivastava A.S., Kurokawa T.; Experimental induction of jaw and gill skeletal malformation in Japanese flounder, Paralichthys olivaceus, larvae. Aquaculture, 185: 175-187, 2000.
   46. Suzuki T., Srivastava A.S., Kurokawa T.; Hoxb-5 is expressed in gill arch 5 during pharyngeal arch Development of flounder Paralichthys olivaceus embryos. Int.J.Dev.Biol, 43:357-559, (1999).
   47. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 1. Nat. Cent. Biotech. Infor., USA, AB029750, (1999).
   48. 43. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 2. Cent. Biotech. Infor., USA, AB029751, (1999).
   49. 44. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 3. Cent. Biotech. Infor., USA, AB029752, (1999).
   50. 45. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 1. Cent. Biotech. Infor., USA, AB029753 (1999).
   51. 46. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 2. Cent. Biotech. Infor., USA, AB029754 (1999).
   52. 47. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 1 precursor. Cent. Biotech. Infor., USA, AB029755, (1999).
   53. 48. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 2 precursor. Cent. Biotech. Infor., USA, AB029756, (1999).
   54. 49. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 3 precursor. Cent. Biotech. Infor., AB029757, (1999).
   55. 50. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 4 precursor. Cent. Biotech. Infor., USA, AB029758, (1999).
   56. Srivastava A.S., Oohara I., Suzuki T., Singh S.N.; Activity and expression of aspartate aminotransferase during reproductive cycle of a fresh water fish, Clarias batrachus. Fish Physiol.Biochem., 20:243-250,1999.
   57. Srivastava A.S., Oohara I., Suzuki T., Singh S.N.; Activity and expression of Glutamate Oxaloacetate Transaminase during reproductive cycle of a fresh water fish Labeo rohita. Fisheries Science, 64(4):621-626,1998.
   58. Srivastava A.S., Trigun S.K., Singh S.N.; Activity of cytosolic and mitochondrial alanin aminotransferase during pre-spawning phase in air-breathing and non air-breathing fishes. J.Sci.Res., 47:33-38,1997.